Literature DB >> 16217075

Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.

W Küker1, T Nägele, E Thiel, M Weller, U Herrlinger.   

Abstract

The authors investigated the applicability of Macdonald response criteria to patients with primary CNS lymphoma (PCNSL). Four of 68 patients with persisting contrast-enhancing lesions after primary therapy did not receive further therapy, and none showed tumor progression after up to 54 months. Because contrast enhancement may not necessarily indicate residual, biologically active lymphoma, the authors propose a modification of the Macdonald response criteria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16217075     DOI: 10.1212/01.wnl.0000178894.51436.54

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma.

Authors:  Jian He; Jian Wu; Yuchen Jiao; Fausto J Rodriguez; Jaishri O Blakeley; Kenneth W Kinzler; Nickolas Papadopoulos; Bert Vogelstein; Matthias Holdhoff
Journal:  J Neurooncol       Date:  2013-07-05       Impact factor: 4.130

2.  Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.

Authors:  Agnieszka Korfel; Thomas Elter; Eckhard Thiel; Matthias Hänel; Robert Möhle; Roland Schroers; Marcel Reiser; Martin Dreyling; Jan Eucker; Christian Scholz; Bernd Metzner; Alexander Röth; Josef Birkmann; Uwe Schlegel; Peter Martus; Gerard Illerhaus; Lars Fischer
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

3.  Post-treatment T1 shortening in primary CNS lymphoma.

Authors:  Sasan Karimi; Vaios Hatzoglou; Vineet Punia; Sasan Partovi; Lauren E Abrey; Lisa M Deangelis
Journal:  J Neurooncol       Date:  2012-10-17       Impact factor: 4.130

Review 4.  Diagnosis and treatment of primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937

Review 5.  Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature.

Authors:  Cristina Izquierdo; Roser Velasco; Noemí Vidal; Juan José Sánchez; Andreas A Argyriou; Sarah Besora; Francesc Graus; Jordi Bruna
Journal:  Neuro Oncol       Date:  2015-09-27       Impact factor: 12.300

6.  Neurological misdiagnoses of lymphoma.

Authors:  Chen Makranz; David Arkadir; Boaz Nachmias; Moshe E Gatt; Ruth Eliahou; Karine Atlan; Anat Mordechai; Netta Goldshmit; Alexander Lossos
Journal:  Neurol Sci       Date:  2020-09-24       Impact factor: 3.307

7.  Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.

Authors:  Kristoph Jahnke; Leslie L Muldoon; Csanad G Varallyay; Seth J Lewin; Robert D Brown; Dale F Kraemer; Carole Soussain; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2009-01-21       Impact factor: 12.300

8.  Primary central nervous system lymphoma.

Authors:  Hendrik Pels; Uwe Schlegel
Journal:  Curr Treat Options Neurol       Date:  2006-07       Impact factor: 3.972

9.  Comparison of Measurement Techniques and Response Criteria for MR Imaging Follow-up in Adult Primary Central Nervous System Lymphoma.

Authors:  K Massicotte-Tisluck; D Vanderweyen; J-F Vendrell; D Fortin; G Gahide
Journal:  AJNR Am J Neuroradiol       Date:  2021-04-29       Impact factor: 4.966

10.  HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis.

Authors:  Sabine Seidel; Agnieszka Korfel; Thomas Kowalski; Michelle Margold; Fatme Ismail; Roland Schroers; Alexander Baraniskin; Hendrik Pels; Peter Martus; Uwe Schlegel
Journal:  Neurol Res Pract       Date:  2019-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.